Skip to content
Nutrition & metabolismCohort study4 min read

Type 2 diabetes: two years of HbA1c and glucose swings predicted later complications

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. · Cardiovascular diabetology · 2018 · Original paper ↗

Key takeaway

In 654 people with type 2 diabetes followed for a median 9.3 years, larger visit-to-visit variability in HbA1c or fasting glucose over 24 months predicted cardiovascular events, kidney outcomes and death, and often did so better than mean HbA1c. Variability did not predict retinopathy overall, and the abstract gives no effect sizes or sample details beyond counts.

Study design

Cohort study

Reading basis

Published abstract

Reading focus

Association & confounding

The research question

HbA1c averages blood sugar over weeks, but it does not show how much glucose swings from one visit to the next. The authors asked whether that visit-to-visit variability adds prognostic information about micro- and macrovascular complications and all-cause mortality in people with type 2 diabetes.

Who and how

Prospective cohort of 654 individuals (the Rio de Janeiro Type 2 Diabetes Cohort Study) followed for a median of 9.3 years. Glycemic variability, measured as standard deviations and coefficients of variation of HbA1c and fasting glycaemia, was calculated over the first 12 and 24 months. Multivariate Cox models, adjusted for risk factors and for mean HbA1c and fasting glycaemia, examined microvascular outcomes (retinopathy, microalbuminuria, renal function deterioration, peripheral neuropathy), macrovascular outcomes (cardiovascular events, major adverse cardiovascular events, cardiovascular mortality) and all-cause mortality.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    During follow-up, 128 patients had a cardiovascular event (96 major adverse events) and 158 died (67 from cardiovascular diseases). 152 had new or worsened retinopathy, 183 reached the renal composite outcome (89 new microalbuminuria and 91 deteriorated renal function) and 96 had new or worsened peripheral neuropathy.
  2. 2
    Variability, especially over 24 months and whether measured by HbA1c or fasting glucose, predicted all endpoints except development or progression of retinopathy and peripheral neuropathy, and was a better predictor than mean HbA1c.
  3. 3
    In patients with good glycemic control (HbA1c ≤ 7.5%, 58 mmol/mol), variability predicted retinopathy development or progression, and it predicted new-onset peripheral neuropathy.

Limits & uncertainty

  1. 1
    The abstract gives no hazard ratios or confidence intervals, so the strength of prediction cannot be judged.
  2. 2
    Variability was calculated over the first 12 and 24 months, so it needs at least two years of regular measurements and cannot guide short-term decisions.
  3. 3
    Predicting is not causing: unstable glucose may mark other problems, such as adherence or illness, rather than itself harm the body.
  4. 4
    This reading is based on the abstract only, and only 654 people from one cohort were studied.

What to take from it

This supports the idea that steadier glucose control over time may be a useful goal alongside a good average, but the study cannot show that smoothing out the swings would prevent complications. People with diabetes should discuss targets and testing frequency with their clinician rather than changing treatment on their own.

Reading your own data

If you use a continuous glucose monitor or log fasting glucose, the spread of your readings (not only the average) is something you can follow. Compare across weeks and months with the same meter or sensor, and keep in mind that the measure in this paper came from clinic HbA1c and fasting tests over 12 to 24 months.

How to read this evidence

Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Long-term visit-to-visit glycemic variability is an additional measure of glycemic control. We aimed to evaluate the prognostic value of several measures of glycemic variability for the occurrence of micro- and macrovascular complications, and all-cause mortality in patients with type 2 diabetes.

Methods

654 individuals were followed-up over a median of 9.3 years. Glycemic variability (SDs and coefficients of variation of HbA_(1c) and fasting glycaemia) was measured during the first 12- and 24-months. Multivariate Cox analysis, adjusted for risk factors and mean HbA_(1c) and fasting glycaemia levels, examined the associations between glycemic variability and the occurrence of microvascular (retinopathy, microalbuminuria, renal function deterioration, peripheral neuropathy) and macrovascular complications [total cardiovascular events (CVE), major adverse CVEs (MACE) and cardiovascular mortality], and of all-cause mortality.

Results

During follow-up, 128 patients had a CVE (96 MACE), and 158 patients died (67 from cardiovascular diseases); 152 newly-developed or worsened diabetic retinopathy, 183 achieved the renal composite outcome (89 newly developed microalbuminuria and 91 deteriorated renal function), and 96 newly-developed or worsened peripheral neuropathy. Glycemic variability, particularly the 24-month parameters either estimated by HbA_(1c) or by fasting glycemia, predicted all endpoints, except for retinopathy and peripheral neuropathy development/progression, and was a better predictor than mean HbA_(1c). Glycemic variability predicted retinopathy development/progression in patients with good glycemic control (HbA_(1c) ≤ 7.5%, 58 mmol/mol) and predicted new-incident peripheral neuropathy.

Conclusions

Long-term visit-to-visit glycemic variability is an additional and frequently a better glycemic parameter than mean HbA_(1c) levels for assessing the risk of future development of micro- and macrovascular complications in patients with type 2 diabetes.

Sources & attribution

Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.

Cardoso CRL, Leite NC, Moram CBM, Salles GF, Salles GF.

Cardiovascular diabetology · 2018-02-24

DOI: 10.1186/s12933-018-0677-0 ↗PubMed · 29477146 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Trial meta-analysis

Early time-restricted eating linked to more weight loss and lower insulin than late eating

Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.

BMJ Medicine

In-depth explainersRead study →
·Randomised trial

An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss

Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.

The New England Journal of Medicine

In-depth explainersRead study →
·Randomised trial

In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain

In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.

Cell Metabolism

In-depth explainersRead study →
·Randomised trial

Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)

Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.

The New England Journal of Medicine

In-depth explainersRead study →
Nutrition & metabolism →